Drug Trial Radar · NCT07310095
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Dec 30, 2025
Primary completion
Sep 15, 2027
Study completion Nov 15, 2027
Sponsor
- Lead sponsor
- Xian-Janssen Pharmaceutical Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
Conditions
- Crohn Disease
Interventions
Guselkumab (GUS)Drug
Guselkumab will be administered intravenously or by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Clinical Remission At Week 48Time frame: At Week 48
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital Sun Yat sen University
Guangzhou, China · Recruiting
The Sixth Affiliated Hospital Sun Yat sen University
Guangzhou, China · Recruiting
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, China · Recruiting
Ruijin Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.